Successful Treatment of Recalcitrant Pediatric Pemphigus Vulgaris With Rituximab

Santiago-Vázquez, Marely; González-Molina, Valeria J.; Rodriguez-Ramos, Frances M.; Colón-Fontánez, Francisco; Carrasquillo, Osward Y.

doi:10.1177/00099228221140801

Cited by 6 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, the earliest research on rituximab in the treatment of pemphigus can be traced back to the successful treatment case published by Heizmann, M in 2001 [ 91 ], who proposed that rituximab may be an effective alternative drug for the treatment of PNP. Rituximab can be used alone to treat pemphigus [ 92 , 93 ] or in combination with glucocorticoids, corticosteroids, etc. [ [94] , [95] , [96] ].…”

Section: Discussionmentioning

confidence: 99%

Focus on pemphigus treatment publications: A bibliometric and visual analysis (1992–2022)

Wang,

Huang,

et al. 2024

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Focus on pemphigus treatment publications: A bibliometric and visual analysis (1992–2022)

Wang,

Huang,

et al. 2024

Heliyon

View full text Add to dashboard Cite

“…Nearly all studies reported complete remission on treatment (n=20; 43.4%), off treatment (n=20; 43.4%), or complete remission without the status of ongoing treatment (n=3; 6.5%) or partial remission off treatment (n=2; 4.3%) at the final follow-up visit (n=45/46; 97.8%). Control of disease activity was reported in one case [ 33 ]. Relapses or flares were observed in 18 cases (39.1%) either minor or major, during initial follow-ups.…”

Section: Reviewmentioning

confidence: 99%

“…A total of 18 studies were shortlisted for qualitative synthesis [9,11,[19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34]. The characteristics of the included studies are comprehensively elaborated in Table 2.…”

Section: Study Characteristicsmentioning

confidence: 99%

Rituximab in Childhood and Juvenile Pemphigus Vulgaris: A Systematic Review

Shrivastava,

Mariam,

Abid

et al. 2024

Cureus

View full text Add to dashboard Cite

Pemphigus vulgaris (PV) is a chronic autoimmune blistering disorder characterized by the loss of intraepithelial adhesion, affecting the skin and mucous membranes. Both males and females are affected, although it predominantly affects females in their fifth and sixth decades of life. Approximately 1.4 to 3.7% of PV cases occur in the pediatric population (≤18 years of age), and may be classified into childhood/pediatric PV, which affects individuals under 12 years old, and juvenile/adolescent PV, affecting those between 12 and 18 years old. Due to its rare occurrence in children and adolescents, there is often a delay in diagnosis and treatment in this age group. A systematic literature search was conducted on MEDLINE/PubMed, Web of Science, EMBASE, SCOPUS, and Cochrane Library databases to evaluate the efficacy of rituximab (RTX) in childhood and juvenile PV patients. The Joanna Briggs Institute (JBI) Critical Appraisal Checklist was employed to assess the risk of bias in case reports and series, while the Cochrane ROBINS-I tool was utilized for evaluating observational studies or non-randomized intervention studies. A total of 18 studies encompassing 46 juvenile or childhood PV patients in the pediatric and adolescent age groups were included for qualitative synthesis. The studies included nine case reports, two case series, five retrospective studies, one prospective study, and one open-label pilot study. Almost all cases of childhood and juvenile PV achieved either complete or partial remission after undergoing RTX treatment during the final follow-up periods. Furthermore, most cases reported no relapse, and only minor adverse events were noted in the RTX treatment group. Despite its potential benefits, the utilization of RTX in pediatric patients raises concerns due to the scarcity of evidence and the absence of controlled studies specific to this age group. Further exploration is necessary to establish a standardized treatment regimen for RTX in pediatric PV, which involves identifying the optimal dosage, frequency, treatment cycle duration, and maintenance therapy duration.

show abstract

Juvenile pemphigus vulgaris: Literature review and a rare case report

Sriram,

Hasan,

Mansoori

et al. 2024

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessagePemphigus vulgaris (PV) is a chronic autoimmune blistering disorder characterized by the loss of intraepithelial adhesion affecting the skin and mucous membranes, predominantly affects females in their fifth and sixth decades of life. Due to its rare occurrence in children and adolescents, there is often a delay in diagnosis and treatment in this age group. PV should always be considered in the differential diagnosis of oral ulcerative and vesiculobullous lesions in both children and adolescents.

show abstract

Successful Treatment of Recalcitrant Pediatric Pemphigus Vulgaris With Rituximab

Abstract: Figure 1. Note multiple erosions and scattered flaccid bullae involving almost 100% of patient's back.

Cited by 6 publications

References 18 publications

Focus on pemphigus treatment publications: A bibliometric and visual analysis (1992–2022)

Focus on pemphigus treatment publications: A bibliometric and visual analysis (1992–2022)

Rituximab in Childhood and Juvenile Pemphigus Vulgaris: A Systematic Review

Juvenile pemphigus vulgaris: Literature review and a rare case report

Contact Info

Product

Resources

About